regulated endocrine specific protein 18Genealiases: []
Q-omics provides the consensus-scored RESP18 profile across patient tissues and cancer cell-line models. RESP18 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RESP18 is differentially expressed in 3, with the highest sampling consensus in READ. Additionally, RESP18 RNA expression shows 6,890 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, READ, and STAD as cancer lineages where RESP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RESP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RESP18 survival associations across molecular data types. RESP18 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RESP18 RNA expression–survival associations across cancer types. High RESP18 expression shows unfavorable associations in KICH, THYM, READ, UCS, CHOL and UVM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RESP18 RNA expression.
This table summarizes RESP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for RESP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RESP18 shows lower tumor expression in READ, COAD and STAD. The READ box plot shows higher RESP18 RNA expression in normal versus tumor tissue (log2 FC = −0.082, t-test p = .001).
This table shows molecular features associated with RESP18 in patient tissues and cancer cell lines. In patient samples, RESP18 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RESP18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
